Pharmacogenetic testing: not as simple as it seems
Pharmacogenetic testing: not as simple as it seems
复制标题
DOI：
10.1097/gim.0b013e31817701d4
复制
发表时间：
2008-06-01
影响因子：
8.8
通讯作者：
Burke, Wylie
中科院分区：
文献类型：
--
作者：
Haga, Susanne B.;Burke, Wylie
药物遗传学有可能通过为最有可能受益的患者量身定制合适的药物和剂量来帮助指导治疗决策。这种直截了当的临床目标使得一些人认为药物遗传学检测是没有伦理问题的。然而，在考虑在临床护理中使用这些新工具时，出现了许多潜在的风险和临床不确定性。我们建议对药物遗传测试进行分类，以确定和优先考虑需要解决的政策问题，以确保药物遗传测试的适当提供。我们使用分类框架来考虑与辅助信息、检测时间以及卫生专业人员药物遗传学检测结果的存储和检索相关的获益和风险。这些问题对知情同意和遗传咨询要求以及卫生专业人员的作用都有影响。
Pharmacogenetics has the potential to help guide treatment decisions by tailoring appropriate drugs and dosages to patients most likely to benefit. This straightforward clinical goal has led some to suggest that pharmacogenetic testing is free of ethical concerns. However, a number of potential risks and clinical uncertainties arise in considering the use of these new tools in clinical care. We propose a classification of pharmacogenetic tests to identify and prioritize the policy issues that will need to be addressed to ensure appropriate delivery of pharmacogenetic testing. We use the classification framework to consider the benefits and risks associated with ancillary information, timing of testing, and storage and retrieval of pharmacogenetic test results among health professionals. These issues have implications for informed consent and genetic counseling requirements, and for the role of health professionals.